We are happy to announce the official publication of the study "SimSearch: A Human-in-the-loop learning framework for fast detection of regions of interest in microscopy images”, demonstrating Vironova’s technology leadership in AI-based research...
Vironova is proud to announce the promotion of its Chief Technology Officer (CTO) Ida-Maria Sintorn to Professor of Computerized Image Processing at Uppsala University, Department of Information Technology, as of 1 July, 2022.
GeneNova, a new innovation milieu with the goal to develop novel production methods for adeno-associated virus based gene therapies, has just been launched.
2020-06-15: Shareholders of Vironova AB (publ), 556678-1463, are hereby summoned to our annual general meeting which will be held on July 15 , 2022, at 14:00 at the company´s premise at Gävlegatan 22, Stockholm.
2020-06-14: The Annual General Meeting will be moved from June 30, 2022 to July 15, 2022 at 14.00. A new notice of the Annual General Meeting will be issued shortly. The Annual General Meeting will be held at the company's premises at Gävlegatan 22...
We are happy to present a joint Vironova/Takeda study (PLoS ONE 17(6): e0269139) demonstrating a validated cryogenic TEM-based (cryoTEM) method to visualize, quantify, and assess the genome packaging in recombinant adeno-associated virus (rAAV)...
New scientific publication showing Vironova’s technology leadership in AI research for bioimage applications and engagement in academic-industry collaboration. Access the paper ahead of publication.
Prevas has signed an agreement for the acquisition of 100 percent of BitSim NOW AB. BitSim NOW is a consulting firm in Stockholm with 35 employees focusing on innovative product development.
The Board of Directors has been in contact with the major shareholders and has decided in a positive spirit that it will work towards a broadening of the Board of Directors, increased financial information and a greater spread of Class A shares in...
Finding critical quality parameters using TEM-based image analysis
TEM analysis of purity, integrity and formulation changes in the production of viral vectors and vaccines
Harnessing the power of TEM and AI for rapid and routine analytical insights for gene therapy development
Currently no scheduled events
Please visit our Career site